Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BART L SCOTT

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1285724138
CMS profile
149253
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$240,633.35

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BART L SCOTT

NPI 1285724138 · CMS profile ID 149253

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285724138?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BART L SCOTT, NPI 1285724138, CMS profile ID 149253. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285724138?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BART L SCOTT, NPI 1285724138, CMS profile ID 149253. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285724138?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BART L SCOTT, NPI 1285724138, CMS profile ID 149253, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1285724138?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $240,633.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $65.5411/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892029 CMS
GlaxoSmithKline, LLC. $13.5711/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892031 CMS
GlaxoSmithKline, LLC. $55.9011/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892035 CMS
GlaxoSmithKline, LLC. $6,000.0011/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892037 CMS
GlaxoSmithKline, LLC. $18.8811/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892039 CMS
GlaxoSmithKline, LLC. $22.1011/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892043 CMS
Incyte Corporation $309.5011/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943018781 CMS
Incyte Corporation $114.4411/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943018783 CMS
Incyte Corporation $200.4811/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943018785 CMS
Incyte Corporation $115.6111/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943018773 CMS
Incyte Corporation $150.7111/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943018787 CMS
Incyte Corporation $65.6611/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943018803 CMS
Novartis Pharmaceuticals Corporation $1,012.5010/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894342155 CMS
E.R. Squibb & Sons, L.L.C. $259.5010/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710923 CMS
E.R. Squibb & Sons, L.L.C. $716.8610/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710861 CMS
GlaxoSmithKline, LLC. $178.9210/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892033 CMS
GlaxoSmithKline, LLC. $82.4910/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892041 CMS
GlaxoSmithKline, LLC. $72.9210/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892047 CMS
E.R. Squibb & Sons, L.L.C. $1,200.0010/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710885 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0010/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710921 CMS
GlaxoSmithKline, LLC. $181.2610/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892045 CMS
Alexion Pharmaceuticals, Inc. $3,000.0010/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915789103 CMS
CTI BioPharma Corp. $1,200.0010/11/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965230119 CMS
CTI BioPharma Corp. $900.0010/11/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965230121 CMS
E.R. Squibb & Sons, L.L.C. $4,310.0010/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710841 CMS
Blueprint Medicines Corporation $219.0310/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940053 CMS
Blueprint Medicines Corporation $6,468.0010/05/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940057 CMS
Blueprint Medicines Corporation $18.3410/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940061 CMS
CTI BioPharma Corp. $30.9809/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933542819 CMS
E.R. Squibb & Sons, L.L.C. $505.7109/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710879 CMS
Alexion Pharmaceuticals, Inc. $19.1209/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914638639 CMS
Alexion Pharmaceuticals, Inc. $20.0509/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914792267 CMS
Alexion Pharmaceuticals, Inc. $76.9609/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915065507 CMS
Alexion Pharmaceuticals, Inc. $98.3809/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915853567 CMS
CTI BioPharma Corp. $3,800.0009/29/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933542849 CMS
Blueprint Medicines Corporation $403.9709/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940037 CMS
GlaxoSmithKline, LLC. $610.0809/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944892025 CMS
Blueprint Medicines Corporation $129.9709/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940049 CMS
Alexion Pharmaceuticals, Inc. $3,250.0009/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915580891 CMS
Blueprint Medicines Corporation $80.0009/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940041 CMS
Blueprint Medicines Corporation $492.2009/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958940045 CMS
E.R. Squibb & Sons, L.L.C. $117.5809/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710839 CMS
E.R. Squibb & Sons, L.L.C. $789.0009/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932710843 CMS
Alexion Pharmaceuticals, Inc. $1,000.0009/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915817151 CMS
Alexion Pharmaceuticals, Inc. $291.5709/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914802295 CMS
Alexion Pharmaceuticals, Inc. $245.0009/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914888147 CMS
Alexion Pharmaceuticals, Inc. $31.6409/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914891289 CMS
Alexion Pharmaceuticals, Inc. $191.6009/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914913553 CMS
Alexion Pharmaceuticals, Inc. $130.6509/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915729053 CMS
Alexion Pharmaceuticals, Inc. $291.5609/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914705941 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $152,195.34 161
PY2020 $115,468.17 73
PY2021 $133,592.82 108
PY2022 $240,633.35 220
PY2023 $217,942.92 184
PY2024 $273,956.43 210
PY2025 $209,823.76 178

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,070,279.49 39
PY2024 Principal investigator $158,750.34 1
PY2023 Principal investigator $250,083.83 7
PY2022 Principal investigator $171,338.82 8
PY2021 Recipient $2,100.00 1
PY2021 Principal investigator $603,427.02 14
PY2020 Principal investigator $147,708.07 5
PY2019 Recipient $6,698.14 3
PY2019 Principal investigator $405,876.35 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,017.27 12/17/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211417631
Principal investigator 1 TAIHO ONCOLOGY, INC. $39,059.10 11/11/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416240
Principal investigator 1 ABBVIE INC. $85,050.00 10/30/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202519725
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,017.27 10/17/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419775
Principal investigator 1 TAIHO ONCOLOGY, INC. $15,261.70 09/25/2025 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211420503
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,017.27 09/16/2025 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211420501
Principal investigator 1 TAIHO ONCOLOGY, INC. $11,653.20 09/01/2025 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419031
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,017.27 08/12/2025 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416242
Principal investigator 1 TAIHO ONCOLOGY, INC. $31,188.60 07/28/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415529
Principal investigator 1 TAIHO ONCOLOGY, INC. $9,293.00 07/28/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419773
Principal investigator 1 TAIHO ONCOLOGY, INC. $253,322.00 07/16/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211417629
Principal investigator 1 TAIHO ONCOLOGY, INC. $20,055.00 07/16/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419029
Principal investigator 1 SOBI, INC $39,173.00 07/10/2025 Non-covered Recipient Entity
Fred Hutchinson Cancer Center
PAC601 No dispute reported 06/30/2026 1240177553
Principal investigator 1 TAIHO ONCOLOGY, INC. $12,430.00 07/09/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416940
Principal investigator 1 TAIHO ONCOLOGY, INC. $94,988.00 07/04/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416938
Principal investigator 1 TAIHO ONCOLOGY, INC. $37,977.70 07/03/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211418359
Principal investigator 1 TAIHO ONCOLOGY, INC. $28,727.10 06/02/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416246
Principal investigator 1 Geron Corporation $1,134.73 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895259
Principal investigator 1 Geron Corporation $2,850.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895263
Principal investigator 1 Geron Corporation $37,500.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895267
Principal investigator 1 Geron Corporation $1,273.16 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895271
Principal investigator 1 Geron Corporation $3,900.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895275
Principal investigator 1 Geron Corporation $34,195.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895279
Principal investigator 1 Geron Corporation $1,640.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895283
Principal investigator 1 Geron Corporation $7,247.89 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895287
Principal investigator 1 Geron Corporation $2,026.41 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895291
Principal investigator 1 Geron Corporation $1,333.50 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895295
Principal investigator 1 Geron Corporation $318.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895299
Principal investigator 1 Geron Corporation $897.31 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895303
Principal investigator 1 Geron Corporation $948.02 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895307
Principal investigator 1 Geron Corporation $1,091.57 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895311
Principal investigator 1 Geron Corporation $831.22 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895315
Principal investigator 1 Geron Corporation $4,500.00 05/22/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment No dispute reported 06/30/2026 1238895319
Principal investigator 1 TAIHO ONCOLOGY, INC. $11,649.60 05/15/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416942
Principal investigator 1 TAIHO ONCOLOGY, INC. $57,527.50 04/28/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416244
Principal investigator 1 TAIHO ONCOLOGY, INC. $26,879.40 04/02/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419033
Principal investigator 1 TAIHO ONCOLOGY, INC. $184,884.20 04/02/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211419035
Principal investigator 1 Geron Corporation $3,154.50 02/21/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894259
Principal investigator 1 Geron Corporation $2,250.00 02/21/2025 Non-covered Recipient Entity
FRED HUTCHINSON CANCER CENTER
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis No dispute reported 06/30/2026 1238894264